Found: 10
Select item for more details and to access through your institution.
Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1891, doi. 10.1007/s13555-024-01201-4
- By:
- Publication type:
- Article
Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 2, p. 421, doi. 10.1007/s13555-023-01089-6
- By:
- Publication type:
- Article
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2589, doi. 10.1007/s13555-023-00977-1
- By:
- Publication type:
- Article
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 9, p. 2019, doi. 10.1007/s13555-023-00975-3
- By:
- Publication type:
- Article
Economic Burden of Comorbidities in Patients with Psoriasis in the USA.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 207, doi. 10.1007/s13555-022-00832-9
- By:
- Publication type:
- Article
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 9, p. 2087, doi. 10.1007/s13555-022-00775-1
- By:
- Publication type:
- Article
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-tohigh risk acute coronary syndrome and planned percutaneous coronary intervention.
- Published in:
- Pharmacy Practice (1886-3655), 2014, v. 12, n. 3, p. 1, doi. 10.4321/S1886-36552014000300007
- By:
- Publication type:
- Article
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-tohigh risk acute coronary syndrome and planned percutaneous coronary intervention.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs.
- Published in:
- Rheumatology & Therapy, 2022, v. 9, n. 4, p. 1091, doi. 10.1007/s40744-022-00453-w
- By:
- Publication type:
- Article